{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:45:13Z","timestamp":1791852313077,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA100730"],"award-info":[{"award-number":["CA100730"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA063417"],"award-info":[{"award-number":["CA063417"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA234640"],"award-info":[{"award-number":["CA234640"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014571","name":"Alvin J. Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["26652"],"award-info":[{"award-number":["26652"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Adult T-cell leukemia lymphoma (ATLL) is a chemotherapy-resistant malignancy with a median survival of less than one year that will afflict between one hundred thousand and one million individuals worldwide who are currently infected with human T-cell leukemia virus type 1. Recurrent somatic mutations in host genes have exposed the T-cell receptor pathway through nuclear factor \u03baB to interferon regulatory factor 4 (IRF4) as an essential driver for this malignancy. We sought to determine if IRF4 represents a therapeutic target for ATLL and to identify downstream effectors and biomarkers of IRF4 signaling in vivo.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>ATLL cell lines, particularly Tax viral oncoprotein-negative cell lines, that most closely resemble ATLL in humans, were sensitive to dose- and time-dependent inhibition by a next-generation class of IRF4 antisense oligonucleotides (ASOs) that employ constrained ethyl residues that mediate RNase H-dependent RNA degradation. ATLL cell lines were also sensitive to lenalidomide, which repressed IRF4 expression. Both ASOs and lenalidomide inhibited ATLL proliferation in vitro and in vivo<jats:italic>.<\/jats:italic> To identify biomarkers of IRF4-mediated CD4\u2009+\u2009T-cell expansion in vivo<jats:italic>,<\/jats:italic> transcriptomic analysis identified several genes that encode key regulators of ATLL, including interleukin 2 receptor subunits \u03b1 and \u03b2, KIT ligand, cytotoxic T-lymphocyte-associated protein 4, and thymocyte selection-associated high mobility group protein TOX 2.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These data support the pursuit of IRF4 as a therapeutic target in ATLL with the use of either ASOs or lenalidomide.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12977-020-00535-z","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T14:02:59Z","timestamp":1598623379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Daniel A.","family":"Rauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemalatha","family":"Sundaramoorthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Robert","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Challen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-7294","authenticated-orcid":false,"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"535_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"key":"535_CR2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/jit497","volume":"209","author":"YB Chang","year":"2014","unstructured":"Chang YB, Kaidarova Z, Hindes D, Bravo M, Kiely N, Kamel H, Dubay D, Hoose B, Murphy EL. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors - United States, 2000\u20132009. J Infect Dis. 2014;209:523\u201331.","journal-title":"J Infect Dis"},{"key":"535_CR3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-15-0303","volume":"4","author":"H Ureshino","year":"2016","unstructured":"Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, et al. Effector regulatory T-cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4:644\u20139.","journal-title":"Cancer Immunol Res."},{"key":"535_CR4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group. Br J Hematol. 1991;79:428\u201337.","journal-title":"Br J Hematol"},{"key":"535_CR5","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Ike N, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570\u20137.","journal-title":"Blood"},{"key":"535_CR6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","volume":"134","author":"DA Rauch","year":"2019","unstructured":"Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang XX, Ren X, Olson S, Cheng X, et al. Rapid progression of adult T-cell leukemia\/lymphhoma as tumor infiltrating Treg cells after PD-1 blockade. Blood. 2019;134:1406\u201314.","journal-title":"Blood"},{"key":"535_CR7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al. Integrated molecular analysis of adult T-cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"535_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fmicb.2012.00406","volume":"3","author":"R Currer","year":"2012","unstructured":"Currer R, VanDuyne R, Jaworski E, Guendel I, Sampey G, Das R, Narayanan A, Kashanchi F. HTLV Tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol. 2012;3:406.","journal-title":"Front Microbiol"},{"key":"535_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-4690-5-76","volume":"5","author":"M Boxus","year":"2008","unstructured":"Boxus M, Twizere J-C, Legros S, Dewulf J-F, Kettmann R, Willems L. The HTLV-I Tax interactome. Retrovirology. 2008;5:76.","journal-title":"Retrovirology"},{"key":"535_CR10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/cas.13948","volume":"110","author":"M Kannagi","year":"2019","unstructured":"Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy. Cancer Sci. 2019;110:849\u201357.","journal-title":"Cancer Sci"},{"key":"535_CR11","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood.2019002665","volume":"135","author":"A Rowan","year":"2020","unstructured":"Rowan A, Dillon R, Witkover A, Melamed A, Demontis M-A, Gillet N, Mun LJ, Bangham C, Cook L, Fields P, Taylor G. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis. Blood. 2020;135:2023\u201332.","journal-title":"Blood."},{"key":"535_CR12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.2019002639","volume":"135","author":"RWJ Wong","year":"2020","unstructured":"Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, et al. Feed-forward regulatory loop driven by IRF4 and NF-kB in adult T-cell luekmeia\/lymphoma. Blood. 2020;135:934\u201347.","journal-title":"Blood"},{"key":"535_CR13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1349-7006.2001.tb02151.x","volume":"92","author":"Y Imaizumi","year":"2001","unstructured":"Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M, Matsuyama T. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92:1284\u201392.","journal-title":"Jpn J Cancer Res"},{"key":"535_CR14","doi-asserted-by":"crossref","first-page":"e1006597","DOI":"10.1371\/journal.ppat.1006597","volume":"13","author":"L Sawada","year":"2017","unstructured":"Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, Sato T, Yamano Y, Tanaka Y, Masuda T, Kannagi M. IL-10-mediated signals act as a switch for lymphoproliferation in human T-cell leukmeia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13:e1006597.","journal-title":"PLoS Pathog"},{"key":"535_CR15","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2006-07-036368","volume":"109","author":"JC Ramos","year":"2007","unstructured":"Ramos JC, Ruiz P, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE, Toomey NL, Andela V, Harhaj EW, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia\/lymphoma. Blood. 2007;109:3060\u20138.","journal-title":"Blood"},{"key":"535_CR16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa M, Shaffer AL, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petgrus MN, Yang Y, et al. Targeting the HTLV-1-regulated BATF3\/IRF4 transcriptional network in adult T-cell leukemia\/lymphoma. Cancer Cell. 2018;34:286\u201397.","journal-title":"Cancer Cell."},{"key":"535_CR17","doi-asserted-by":"crossref","first-page":"21092","DOI":"10.1074\/jbc.M110.200907","volume":"2866","author":"A Refaat","year":"2011","unstructured":"Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I, Sakurai H. Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem. 2011;2866:21092\u20139.","journal-title":"J Biol Chem"},{"key":"535_CR18","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1074\/jbc.RA117.000164","volume":"293","author":"MA Cherian","year":"2018","unstructured":"Cherian MA, Olson S, Sundaramoorthi H, Cates K, Cheng X, Harding J, Martens A, Challen GA, Tyagi M, Ratner L, Rauch D. An activating mutation of IRF4 unique to adult T-cell leukemia. J Biol Chem. 2018;293:6844\u201358.","journal-title":"J Biol Chem."},{"key":"535_CR19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Embre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226\u201331.","journal-title":"Nature"},{"key":"535_CR20","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","volume":"125","author":"A Kritharis","year":"2015","unstructured":"Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125:2471\u20136.","journal-title":"Blood"},{"key":"535_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620716652861","volume":"7","author":"M Arora","year":"2016","unstructured":"Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016;7:209\u201321.","journal-title":"Ther Adv Hematol"},{"key":"535_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","volume":"9","author":"SA Holstein","year":"2018","unstructured":"Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol. 2018;9:175\u201390.","journal-title":"Ther Adv Hematol"},{"key":"535_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2017.06.003","volume":"54","author":"C Talati","year":"2017","unstructured":"Talati C, Sallman D, List A. Lenalidomide: myelodysplastic syndromes with del(51) and beyond. Semin Hematol. 2017;54:159\u201366.","journal-title":"Semin Hematol"},{"key":"535_CR24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2013","unstructured":"Zhu YX, Kortuem KM, Stewart AK. Molecular mechaism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multple myeloma. Leukemia Lymphoma. 2013;54:683\u20137.","journal-title":"Leukemia Lymphoma."},{"key":"535_CR25","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3109\/10428194.2013.861066","volume":"55","author":"E Jourdan","year":"2014","unstructured":"Jourdan E, Leblond V, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Woolridge JE, Moreau PA. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leukemia Lymphoma. 2014;55:2013\u20137.","journal-title":"Leukemia Lymphoma"},{"key":"535_CR26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narta A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Corner E, Li X, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"535_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305\u20139.","journal-title":"Science"},{"key":"535_CR28","doi-asserted-by":"crossref","first-page":"e1546544","DOI":"10.1080\/2162402X.2018.1546544","volume":"8","author":"DA Davis","year":"2018","unstructured":"Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, Tagawa T, Ziegelbauer JM, Franchini G, Yarchoan R. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. Oncoimmunology. 2018;8:e1546544.","journal-title":"Oncoimmunology"},{"key":"535_CR29","first-page":"199","volume-title":"Methods in molecular biology, volume 1402","author":"T Zhou","year":"2016","unstructured":"Zhou T, Kim Y, MacLeod AR. Targeting long noncoding RNA with antisense oligonucleotide technology as cancer therapeutics. In: Zhang YF, et al., editors. Methods in molecular biology, volume 1402. New York: Spring; 2016. p. 199\u2013213."},{"key":"535_CR30","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatenangelo M, Wang M, Ren Y, Cuoto S, Breider M, et al. Rate of CRL4 (CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.","journal-title":"Blood Cancer J"},{"key":"535_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u201321.","journal-title":"Annu Rev Med"},{"key":"535_CR32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, et al. Nusinersen versus sham control in infantile-onset spinal muscular atropy. ENDEAR Study Group. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"535_CR33","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","volume":"18","author":"D Hong","year":"2015","unstructured":"Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al. AZD9150, a next-generation antisense-oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;18:314ra185.","journal-title":"Sci Transl Med"},{"key":"535_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","volume":"16","author":"MJ Reilley","year":"2018","unstructured":"Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, et al. STAT3 antisense oligonucloeotide AZD9150 in a subset of patients with heavily pretreated lymphoma, results of a phase 1b trial. J Immunother Cancer. 2018;16:119.","journal-title":"J Immunother Cancer"},{"key":"535_CR35","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086\u201393.","journal-title":"J Clin Oncol"},{"key":"535_CR36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.immuni.2017.09.001","volume":"47","author":"V Krishnamoorthy","year":"2017","unstructured":"Krishnamoorthy V, Kannaganat S, Maienschein-Cline M, Cook SL, Chen J, Bahroos N, Sievert E, Corse E, Chong A, Sciammas R. The IRF4 gene regulatory module functions as a read-write integrator to dynamically coordinate T helper cell fate. Immunity. 2017;47:481\u201397.","journal-title":"Immunity"},{"key":"535_CR37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V99.2.634","volume":"99","author":"K Nosaka","year":"2002","unstructured":"Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99:634\u201340.","journal-title":"Blood"},{"key":"535_CR38","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.1073\/pnas.1010722107","volume":"107","author":"J Pancewicz","year":"2010","unstructured":"Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O, Nicot C. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010;107:16619\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"535_CR39","doi-asserted-by":"crossref","first-page":"27411","DOI":"10.1074\/jbc.272.43.27411","volume":"272","author":"SR Trejo","year":"1997","unstructured":"Trejo SR, Fahl WE, Ratner L. The tax protein of human T-cell leukemia virus type 1 mediates the transactivation of the c-sis\/platelet-derived growth factor-B promoter through interactions with zinc finger transcription factors Sp1 and NGFI-A\/Egr-1. J Biol Chem. 1997;272:27411\u201321.","journal-title":"J Biol Chem"},{"key":"535_CR40","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1038\/bcj.2016.21","volume":"6","author":"L Ratner","year":"2016","unstructured":"Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6:3408.","journal-title":"Blood Cancer J"},{"key":"535_CR41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/ni.2710","volume":"14","author":"K Man","year":"2014","unstructured":"Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S, Pellegrini M, Belz GT, Smyth GK, Febbraio MA, et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T-cells. Nat Immunol. 2014;14:1155\u201365.","journal-title":"Nat Immunol."}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-00535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12977-020-00535-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-020-00535-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T23:52:34Z","timestamp":1630108354000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-020-00535-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s12977-020-00535-z","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were carried out in a humane fashion and approved by the Institutional Animal Care and Use Committee (IACUC; Animal Welfare Assurance # A-3381\u201301).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs Kim, Zhou, and MacLeod are employed by Ionis Pharmaceuticals who have manufactured the IRF4 ASOs and have ongoing clinical trials with these reagents. Other authors have no funding, honoraria, and stock interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}